Transgene, a biotech company, announced positive Phase I data for TG4050 in Head and Neck Squamous Cell Carcinoma (HNSCC) with 100% disease-free survival after 2 years. Ongoing Phase II trials are progressing with expected results in 2026 and 2027. The company is also preparing for new trials in additional indications. Business is funded until December 2026. Governance updates include new appointments to key positions. Financial results show operating income growth and funding secured until the end of 2026. A conference call is scheduled for more information.

Read more at Globe Newswire: Transgene’s Individualized Neoantigen Therapeutic Cancer